Esperion Therapeutics Inc. (NASDAQ: ESPR) on Friday, plunged -7.36% from the previous trading day, before settling in for the closing price of $2.31. Within the past 52 weeks, ESPR’s price has moved between $0.70 and $3.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 7.64% over the past five years. The company achieved an average annual earnings per share of 80.92%. With a float of $168.54 million, this company’s outstanding shares have now reached $170.42 million.
Let’s look at the performance matrix of the company that is accounted for 240 employees.
Esperion Therapeutics Inc. (ESPR) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc. is 1.10%, while institutional ownership is 48.11%. The most recent insider transaction that took place on Sep 20 ’23, was worth 924. In this transaction Chief Commercial Officer of this company sold 742 shares at a rate of $1.25, taking the stock ownership to the 68,318 shares. Before that another transaction happened on Aug 18 ’23, when Company’s Chief Commercial Officer sold 243 for $1.41, making the entire transaction worth $344. This insider now owns 69,060 shares in total.
Esperion Therapeutics Inc. (ESPR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 80.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc. (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 0.87 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit 0.05 in the next quarter and is forecasted to reach 0.05 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics Inc. (NASDAQ: ESPR) saw its 5-day average volume 7.8 million, a positive change from its year-to-date volume of 6.87 million. As of the previous 9 days, the stock’s Stochastic %D was 6.65%. Additionally, its Average True Range was 0.31.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 45.69%, which indicates a significant increase from 7.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.88% in the past 14 days, which was higher than the 101.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.51, while its 200-day Moving Average is $1.77. Nevertheless, the first resistance level for the watch stands at $2.36 in the near term. At $2.58, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.74. If the price goes on to break the first support level at $1.98, it is likely to go to the next support level at $1.82. Assuming the price breaks the second support level, the third support level stands at $1.60.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 364.70 million based on 185,053K outstanding shares. Right now, sales total 116,330 K and income totals -209,250 K. The company made 32,250 K in profit during its latest quarter, and -56,340 K in sales during its previous quarter.
